Source: Myeloma – Hematology Advisor
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Read More
by | Jan 27, 2023 | Myeloma News | 0 comments
Source: Myeloma – Hematology Advisor
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Read More